BPC-157: What the Research Shows

For laboratory and research use only. The following content is provided for scientific and educational purposes. Olympia Peptides compounds are not intended for human consumption, injection, or clinical use and have not been evaluated by the Food and Drug Administration. This content does not constitute medical advice. See our full disclaimer.

BPC-157 — Body Protection Compound-157 — is among the most extensively studied synthetic peptides in the preclinical research literature. A 15-amino-acid sequence derived from a region of human gastric juice protein, BPC-157 has been investigated across a wide range of animal model research contexts over more than two decades of published study. This overview is written for researchers and laboratory professionals seeking a scientific, evidence-grounded orientation to the published BPC-157 research landscape. All claims are research-contextual; BPC-157 is supplied by Olympia Peptides for laboratory research use only and has not been evaluated by the FDA for any clinical application.

What Is BPC-157?

BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid chain — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (single-letter: GEPPPGKPADDAGLV). It has a molecular weight of approximately 1419.5 Da and a molecular formula of C₆₂H₁₀₆N₁₆O₂₂.

BPC-157 is described in the scientific literature as a partial sequence of body protection compound, a protein identified in human gastric juice. The peptide is stable in human gastric juice in vitro — a property that has made it of interest to researchers studying gastrointestinal biology. In its synthetic form, BPC-157 is water-soluble and has been used in a substantial number of rodent and in vitro studies investigating various biological processes.

BPC-157 is not an approved pharmaceutical compound. It is not a dietary supplement. It is researched as a synthetic peptide in preclinical models and has not completed clinical trials for any indication.

Published Research Landscape

Tissue Repair and Wound Healing Models

A significant portion of the published BPC-157 research has been conducted in rodent wound and tissue injury models. Studies published in the Journal of Physiology-Paris by Sikiric and colleagues — who have produced much of the foundational BPC-157 research — investigated the peptide’s effects in various soft tissue and musculoskeletal injury models in rats. These studies examined outcomes including tendon-to-bone healing timelines, ligament repair, and muscle injury recovery in controlled animal model contexts.

Research published in Inflammatory Bowel Diseases and related gastroenterology journals has investigated BPC-157 in the context of gastrointestinal mucosal injury models, including models of NSAID-induced gastric lesions and colitis in rodents. These studies are conducted in preclinical settings; the findings describe animal model outcomes and proposed mechanisms and do not constitute evidence of efficacy in humans.

Published work in the European Journal of Pharmacology has examined BPC-157 in the context of various organ stress and systemic injury models in rodents. Across this body of literature, the peptide has been associated — in animal model research — with outcomes related to tissue organization and vascular response.

Angiogenesis Research

Researchers have studied BPC-157 in the context of angiogenesis — the formation of new blood vessels from existing vasculature — in preclinical models. Studies published in peer-reviewed pharmacology journals have investigated the peptide’s association with VEGFR2 (vascular endothelial growth factor receptor 2) signaling pathways in animal tissue, proposing a mechanism by which the peptide may influence vascular development processes. This research is conducted in animal and in vitro models; the proposed mechanisms have not been confirmed in controlled human clinical trials.

Gastrointestinal Research Context

Given BPC-157’s origin as a gastric peptide sequence, a substantial research thread has investigated it in gastrointestinal contexts. Preclinical studies in the World Journal of Gastroenterology and related publications have examined its behavior in models of gastric mucosal integrity, fistula models, and gut motility research. These studies describe animal model findings; no clinical trials have been completed or approved for BPC-157 in gastrointestinal indications.

Mechanism of Action

Multiple proposed mechanisms for BPC-157’s observed preclinical effects have been described in the published literature. These are proposed mechanisms studied in animal and in vitro research — not confirmed clinical mechanisms of action.

• VEGFR2 pathway modulation: Research has proposed that BPC-157 interacts with the vascular endothelial growth factor receptor 2 pathway, potentially influencing angiogenic signaling in tissue injury models. This proposed mechanism has been investigated in animal tissue studies and is described in publications including work by Hrelec and colleagues in the Journal of Physiology-Paris.
• Nitric oxide system involvement: Preclinical research has investigated BPC-157’s relationship with nitric oxide synthesis pathways in rodent models, with investigators proposing a connection between the peptide and endothelial nitric oxide synthase (eNOS) activity in vascular tissue contexts.
• Growth factor upregulation in research models: Animal model studies have observed associations between BPC-157 administration and growth factor expression patterns in tissue, with researchers proposing that this may contribute to the tissue organization effects observed in wound healing models. These are research-level observations in animal models.
• FAK-paxillin pathway: In vitro research has investigated the peptide’s proposed interaction with the focal adhesion kinase (FAK) and paxillin signaling pathways involved in cell migration and adhesion — processes relevant to wound healing biology in research contexts.

All proposed mechanisms described here are derived from preclinical and in vitro research. The translation of these mechanisms to human biology has not been established through controlled clinical trials.

Supply Format for Research

Olympia Peptides supplies BPC-157 in lyophilized powder format in sealed research vials, with full COA documentation including HPLC purity and mass spectrometry identity confirmation. The compound is also available in encapsulated format for applicable laboratory research contexts. All formats are supplied for research use only.

• BPC-157 10mg — lyophilized vial
• BPC-157 Capsules 500mcg
• Bacteriostatic Water — for reconstitution in laboratory settings

Frequently Asked Questions

What does BPC stand for in BPC-157?

BPC stands for Body Protection Compound. BPC-157 is a 15-amino-acid synthetic peptide derived from a protein identified in human gastric juice. The “157” designation refers to the specific sequence within the parent protein. It is a research compound studied in preclinical models; the name does not imply a confirmed clinical mechanism or therapeutic designation.

What research has been published on BPC-157?

BPC-157 has been the subject of a substantial volume of preclinical research, primarily conducted in rodent models by research groups in Croatia and published in peer-reviewed pharmacology and gastroenterology journals including the Journal of Physiology-Paris, the European Journal of Pharmacology, and Inflammatory Bowel Diseases. The research has investigated the peptide in various tissue injury, gastrointestinal mucosal, and vascular biology contexts. No controlled human clinical trials of BPC-157 have been completed and published.

Is BPC-157 the same as a pharmaceutical drug?

No. BPC-157 is a research compound — a synthetic peptide supplied for laboratory use. It is not an FDA-approved pharmaceutical drug, not a dietary supplement, and not a cosmetic ingredient. It has not been evaluated by the FDA for any clinical indication. Its legal classification is as a research chemical for laboratory use only.

What is the molecular weight of BPC-157?

BPC-157 has a molecular weight of approximately 1419.5 Da and a molecular formula of C62H106N16O22. Its sequence is the 15-amino-acid chain GEPPPGKPADDAGLV. These specifications are confirmed by mass spectrometry as part of the COA documentation provided with each Olympia Peptides batch.

How is BPC-157 stored in a laboratory setting?

Lyophilized BPC-157 powder should be stored at -20°C in a sealed vial away from light and moisture. Reconstituted BPC-157 solutions in bacteriostatic water may be stored at 2–8°C for short-term use, or aliquoted and stored at -20°C to -80°C for longer-term retention. Researchers should document storage conditions and reconstitution dates in laboratory records and consult compound-specific stability data for their specific protocol requirements.

What purity does Olympia Peptides’ BPC-157 reach?

Olympia Peptides’ BPC-157 is characterized at 99% purity by HPLC, with identity confirmed by mass spectrometry. Batch-specific COA documentation is available for researchers who require purity and identity verification for their experimental records or institutional sourcing requirements.

Further Reading: TB-500: What the Research Shows • KPV: What the Research Shows • Research Peptide Storage Guide

The above content is provided for informational and educational purposes relating to scientific research only. It does not constitute medical advice, a personal health recommendation, or a treatment protocol. Olympia Peptides products are supplied for laboratory research use only. They are not intended for human consumption, injection, or clinical use, and have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. See our full disclaimer.